
DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor in China
Plus, news about Palatin, Spero and BioAtla:
DBV Technologies’ $306M financing: The French biotech could get up to that amount to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.